Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective to estimate 6-month progression free survival probability of patients with
recurrent malignant glioma treated with Etoposide + Bevacizumab.
Secondary Objectives To evaluate safety & tolerability of Etoposide + Bevacizumab among
patients with recurrent malignant glioma (RMG).
To evaluate radiographic response, progression free survival & overall survival of patients
with recurrent malignant glioma treated with Etoposide + Bevacizumab.